Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2003

View Archived Issues

Company Profile: Transition Therapeutics

Genzyme to acquire SangStat

Akina develops oral drug delivery technology

Two novel series of VR1 antagonists for urinary incontinence, pain, etc.

Galderma presents new PPARgamma agonists with potential in dermatological disorders

BMS claims new IMPDH inhibitors and their use in recent patent

Aventis scientists prepare new antibacterial streptogramin derivatives

Novel alpha7 nAChR agonists in early development at Bayer

New MMP, TACE and/or aggrecanase inhibitors covered by BMS patent

R&D highlights at Neurosearch

Once-daily Adderall XR formulation may be a useful treatment option in children with ADHD

FTC clears Biogen/Idec merger

NexMed enters NexACT R&D agreement for asthma

Novel 5-HT7 receptor agonist modulates REM sleep

Human Genome Sciences and Genentech enter licensing agreement

17-AAG combination regimens studied in new phase Ib trials

Neurosciences Australia and CSIRO form R&D partnership in brain disorders

First pivotal exenatide study produces positive results

MPC-7869 reduces Abeta42 levels more effectively than select NSAIDs

Exelixis reports quarterly progress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...